Russia swerves default as Putin forced into dollar U-turn


Biogen CEO to step down; drugmaker plans further Aduhelm cost cuts

Vounatsos, who will continue in his role until his successor is appointed, was named as the CEO in 2016 and has been at the helm as Biogen developed and launched several flagship drugs including spinal muscular atrophy drug Spinraza, multiple sclerosis drug Vumerity and most recently Aduhelm. Biogen said on Tuesday it was looking at substantially eliminating commercial infrastructure related to the Alzheimer’s drug and plans for more cost cuts, in addition to the current program to save $500 million annually.

Leave a Reply

Your email address will not be published. Required fields are marked *